## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-9.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($54.60)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Mixed Signals from Institutional Investors Cloud Bio-Techne's Outlook ()**
- Source: Aktiencheck | 20251207T050916 | Neutral | Relevance: 98%
-  Bio-Techne (NASDAQ: TECH) is experiencing market indecision after a mixed quarterly earnings report, with institutional investors showing divergent strategies. While some major players like Select Equity Group L.P. and Norges Bank significantly increased their holdings, others like Brown Advisory Inc. trimmed their stakes. The company faces sector headwinds, including reduced biotech funding and pressure from cell therapy clients, but analysts maintain a "Moderate Buy" rating with an implied upside.

**2. Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence**
- Source: Stock Titan | 20251209T113222 | Somewhat-Bullish | Relevance: 98%
-  Bio-Techne (NASDAQ: TECH) has launched its enhanced Leo System, an upgraded Simple Western platform. This system integrates chemiluminescence with dual-channel near-infrared and infrared fluorescence, significantly expanding its multiplexing capabilities for protein analysis. Key features include the ability to quantify up to 24 targets per sample, process 100 capillaries in three hours with reported 5–6% variability, and support 21 CFR Part 11 compliance.

**3. Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis**
- Source: Investing News Network | 20251209T120903 | Bullish | Relevance: 98%
-  Bio-Techne Corporation has launched its enhanced Leo System, powered by Simple Western Technology, which introduces dual-channel fluorescence detection alongside chemiluminescence for advanced protein analysis. This system offers expanded multiplexing capabilities, enabling researchers to quantify multiple targets simultaneously and process up to 100 capillaries within three hours. The new Leo System aims to provide unmatched precision and efficiency for clinical research and drug discovery, supporting 21 CFR Part 11 compliance.

**4. Bio-Techne Announces Expanded Launch Of Next-Generation Leo System**
- Source: Nasdaq | 20251209T120903 | Somewhat-Bullish | Relevance: 97%
- Bio-Techne Corp. (TECH) has announced the expanded launch and first shipment of its next-generation Leo System, aiming to set new standards in protein analysis. The system, powered by Simple Western Technology, features dual-channel fluorescence and chemiluminescence detection, promising enhanced data throughput and efficiency for researchers. This innovation is expected to accelerate critical discoveries and streamline development timelines.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-9.2% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 26.8x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 26.8 |
| Current P/E | 29.7 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.9% to -6.3% (-9.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.3pp (needs >4.0% for momentum thesis). AM_20 at -4.2% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.29% (CS: 9) | Weak |
| RSI_14 | 41.6 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.957x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 1.062x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $58.82
- **Stop Loss:** $54.60 (7.2% risk)
- **Target:** $67.26 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $4,176.22
- **Portfolio %:** 4.18%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*